🚀 VC round data is live in beta, check it out!
Sagimet Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sagimet Biosciences and similar public comparables like Protalix, Karyopharm Therapeutics, Corbus Pharmaceuticals, Tonix Pharmaceuticals and more.
Sagimet Biosciences Overview
About Sagimet Biosciences
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Founded
2006
HQ
Employees
14
Website
Sectors
Financials (LTM)
EV
$71M
Sagimet Biosciences Financials
Sagimet Biosciences reported last 12-month revenue of —.
In the same LTM period, Sagimet Biosciences generated — in gross profit and had net loss of ($54M).
Revenue (LTM)
Sagimet Biosciences P&L
In the most recent fiscal year, Sagimet Biosciences reported revenue of — and EBITDA of ($57M).
Sagimet Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($57M) | XXX | XXX | XXX |
| Net Profit | ($54M) | XXX | ($51M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Sagimet Biosciences Stock Performance
Sagimet Biosciences has current market cap of $184M, and enterprise value of $71M.
Market Cap Evolution
Sagimet Biosciences' stock price is $5.64.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $71M | $184M | 0.9% | XXX | XXX | XXX | $-1.57 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSagimet Biosciences Valuation Multiples
Sagimet Biosciences trades at (1.2x) EV/EBITDA.
EV / Revenue (LTM)
Sagimet Biosciences Financial Valuation Multiples
As of April 11, 2026, Sagimet Biosciences has market cap of $184M and EV of $71M.
Equity research analysts estimate Sagimet Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sagimet Biosciences has a P/E ratio of (3.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $184M | XXX | $184M | XXX | XXX | XXX |
| EV (current) | $71M | XXX | $71M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (1.2x) | XXX | XXX | XXX |
| EV/EBIT | (1.2x) | XXX | (1.2x) | XXX | XXX | XXX |
| P/E | (3.4x) | XXX | (3.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (1.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sagimet Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Sagimet Biosciences Margins & Growth Rates
Sagimet Biosciences' revenue in the last fiscal year declined by (100%).
Sagimet Biosciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $4.1M for the same period.
Sagimet Biosciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 4% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $4.1M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Sagimet Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Protalix | XXX | XXX | XXX | XXX | XXX | XXX |
| Karyopharm Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Corbus Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Tonix Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Acumen Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sagimet Biosciences M&A Activity
Sagimet Biosciences acquired XXX companies to date.
Last acquisition by Sagimet Biosciences was on XXXXXXXX, XXXXX. Sagimet Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Sagimet Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSagimet Biosciences Investment Activity
Sagimet Biosciences invested in XXX companies to date.
Sagimet Biosciences made its latest investment on XXXXXXXX, XXXXX. Sagimet Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Sagimet Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sagimet Biosciences
| When was Sagimet Biosciences founded? | Sagimet Biosciences was founded in 2006. |
| Where is Sagimet Biosciences headquartered? | Sagimet Biosciences is headquartered in United States. |
| How many employees does Sagimet Biosciences have? | As of today, Sagimet Biosciences has over 14 employees. |
| Who is the CEO of Sagimet Biosciences? | Sagimet Biosciences' CEO is David Happel. |
| Is Sagimet Biosciences publicly listed? | Yes, Sagimet Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Sagimet Biosciences? | Sagimet Biosciences trades under SGMT ticker. |
| When did Sagimet Biosciences go public? | Sagimet Biosciences went public in 2023. |
| Who are competitors of Sagimet Biosciences? | Sagimet Biosciences main competitors are Protalix, Karyopharm Therapeutics, Corbus Pharmaceuticals, Tonix Pharmaceuticals. |
| What is the current market cap of Sagimet Biosciences? | Sagimet Biosciences' current market cap is $184M. |
| Is Sagimet Biosciences profitable? | No, Sagimet Biosciences is not profitable. |
| What is the current net income of Sagimet Biosciences? | Sagimet Biosciences' last 12 months net income is ($54M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.